Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Interest Expenses (2019 - 2023)

UroGen Pharma's Interest Expenses history spans 5 years, with the latest figure at $143.6 million for Q4 2023.

  • For Q4 2023, Interest Expenses rose 10.78% year-over-year to $143.6 million; the TTM value through Dec 2023 reached $143.6 million, up 10.78%, while the annual FY2023 figure was $143.6 million, 10.78% up from the prior year.
  • Interest Expenses reached $143.6 million in Q4 2023 per URGN's latest filing, up from $129.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $143.6 million in Q4 2023 to a low of $50.6 million in Q4 2019.
  • Average Interest Expenses over 5 years is $100.3 million, with a median of $100.6 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: skyrocketed 52.12% in 2020, then rose 10.78% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $50.6 million in 2019, then surged by 52.12% to $77.0 million in 2020, then soared by 30.74% to $100.6 million in 2021, then rose by 28.8% to $129.6 million in 2022, then rose by 10.78% to $143.6 million in 2023.
  • Per Business Quant, the three most recent readings for URGN's Interest Expenses are $143.6 million (Q4 2023), $129.6 million (Q4 2022), and $100.6 million (Q4 2021).